“Teva Pharmaceutical Industries Ltd. (TEVA)’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, ….
The medicine, laquinimod, missed the key goal of the study, the Petach Tikva, Israel-based drugmaker said today in a statement. By contrast, a third group of patients who got Avonex, an older injected treatment from Biogen Idec Inc. (BIIB), had fewer relapses than those who got a placebo….
The study reported today, known as Bravo, is the second this year to show disappointing results for the medicine….
“Laquinimod is dead, if not regulatorily, then commercially,” Ori Hershkovitz, a partner at Sphera Funds Management Ltd. in Tel Aviv, said by e-mail…..”